https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-01 / J. Immunol. 2009 Apr;182(7):3960-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-01 / J. Immunol. 2009 Apr;182(7):3960-42009-04-01 00:00:002019-02-15 09:21:54Cutting Edge: TLR-Dependent viral recognition along with type I IFN positive feedback signaling masks the requirement of viral replication for IFN-{alpha} production in plasmacytoid dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):971-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):971-822009-04-01 00:00:002021-11-15 17:01:56Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):951-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):951-622009-04-01 00:00:002021-11-15 17:02:15Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-01 / Pancreas 2009 Apr;38(3):e69-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-01 / Pancreas 2009 Apr;38(3):e69-742009-04-01 00:00:002019-02-15 08:52:34A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-24 / Clin. Cancer Res. 2009 Apr;15(7):2531-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-24 / Clin. Cancer Res. 2009 Apr;15(7):2531-402009-03-24 00:00:002019-02-15 08:49:29Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-16 / Oncologist 2009 Mar;14(3):240-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-16 / Oncologist 2009 Mar;14(3):240-522009-03-16 00:00:002019-02-15 08:32:27Immunotherapy of acute myeloid leukemia: current approaches
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-11 / Blood 2009 May;113(21):5167-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-11 / Blood 2009 May;113(21):5167-752009-03-11 00:00:002019-02-15 08:44:19Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-11 / Cancer Chemother. Pharmacol. 2009 Nov;64(6):1079-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-11 / Cancer Chemother. Pharmacol. 2009 Nov;64(6):1079-832009-03-11 00:00:002019-02-15 09:17:32Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-03 / Cancer Res. 2009 Mar;69(6):2685-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-03 / Cancer Res. 2009 Mar;69(6):2685-932009-03-03 00:00:002019-02-15 08:38:01Coordination of intratumoral immune reaction and human colorectal cancer recurrence
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-01 / Future Oncol 2009 Mar;5(2):187-96
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-01 / Future Oncol 2009 Mar;5(2):187-962009-03-01 00:00:002019-02-15 09:23:58Promising novel immunotherapies and combinations for prostate cancer
